Clinical trials: Sensory Disorder
Advanced Stage Solid Tumors
ATRi Transition Rollover Study
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
- Trial name
- NCT03309150
- Testing
- Berzosertib
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neuralgia, Postherpetic, Diabetic Neuropathy
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
- Conditions
- Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
- Trial name
- NCT00570310
- Testing
- Comparator: pregabalin
- Volunteers
- 104 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke, Cerebrovascular Accident
Driving Neuroplasticity With Nerve Stimulation and Modified CIT
The investigators proposed to evaluate the effectiveness of sustained peripheral nerve stimulation (PNS) to enhance the therapeutic effects of a modified form CIT (mCIT).
- Trial name
- NCT02587234
- Testing
- peripheral nerve stimulation
- Volunteers
- 21 people
- Sponsor
- University of Kentucky
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Cryptogenic Sensory Polyneuropathy
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and…
- Trial name
- PAIN-CONTRoLS (NCT02260388)
- Testing
- Nortriptyline, Duloxetine, Pregabalin
- Where
- 46 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- University of Kansas Medical Center
Autoimmune Hemolytic Anemia
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that…
- Trial name
- NCT03538041
- Testing
- Parsaclisib
- Where
- 12 sites in United States, Austria and 2 more
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Dysautonomia, Familial, Baroreflex Failure Syndrome
Carbidopa for the Treatment of Excessive Blood Pressure Variability
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated…
- Trial name
- CarbiFD (NCT02553265)
- Testing
- Carbidopa Low-Dose, Carbidopa High-Dose
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- NYU Langone Health
Small-cell Lung Cancer
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC).
- Trial name
- NCT04768296
- Testing
- Berzosertib, Topotecan
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 76 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Phantom Limb
Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees
Individuals with upper-limb amputation usually have intact nerves within the residual limb, and studies have demonstrated that electrical stimulation of those nerves can produce sensations that appear to emanate from the…
- Trial name
- PhantomLimb (NCT02684201)
- Testing
- Boston Scientific Stimulator Lead
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lee Fisher, PhD
Vestibular Disorder
Testing an Intraoral Electronic Balance Aid for Vestibular Imbalance
The human body uses vestibular feedback in coordination with visual and somatosensory information to maintain balance and posture.
- Trial name
- NCT02735096
- Testing
- EquiCue (Intraoral Electronic Balance Aid)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Innervo Technology LLC
Traumatic Brain Injury, Vestibular Deficits
Traditional Balance vs Vibrotactile Feedback Training for Vestibular Rehabilitation
The goal of this clinical research study at RIC is to determine the value and benefit of the SK multimodal balance training system through independent clinical evaluations.
- Trial name
- NCT01672658
- Testing
- Sensory Kinetics Balance System, Traditional Vestibular Rehabilitation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Shirley Ryan AbilityLab
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
RATIONALE: Chemoprotective drugs, such as calcium gluconate and magnesium sulfate, may prevent neurotoxicity caused by oxaliplatin.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Trial name
- NCT01099449
- Testing
- calcium gluconate, magnesium sulfate, oxaliplatin
- Where
- 405 sites in United States, Puerto Rico
- Volunteers
- 362 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive…
- Trial name
- BYLieve (NCT03056755)
- Testing
- Alpelisib, Fulvestrant, Letrozole
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Laryngeal Diseases
Treatment of Chronic Laryngitis With Amitriptyline
This randomized, double-blind, placebo-controlled trial will compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis.
- Trial name
- NCT02552225
- Testing
- Amitriptyline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Medical Center
Urge Incontinence
Effectiveness of eCoin at Sensory and Subsensory Amplitudes
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI).
- Trial name
- ESSENCE (NCT05882318)
- Testing
- eCoin Peripheral Neurostimulator System
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- Valencia Technologies Corporation
Colorectal Cancer, Neurotoxicity
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
RATIONALE: Calcium gluconate and magnesium sulfate may prevent or lessen neurotoxicity caused by oxaliplatin. It is not yet known whether calcium gluconate and magnesium sulfate are more effective than a placebo in preventing…
- Trial name
- NCT00316914
- Testing
- calcium gluconate, magnesium sulfate
- Where
- 14 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Spinal Cord Injuries
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
To investigate the clinical effect of detrusor botulinum toxin A (BoNT-A) injection on neurogenic detrusor overactivity (NDO) and renal function and to compare the difference of expressions of sensory receptors and nerve growth…
- Trial name
- NCT01682603
- Testing
- Botulinum toxin A
- Where
- Taiwan
- Volunteers
- 34 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Mild Cognitive Impairment, Cognitive Decline
Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments
The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
- Trial name
- NCT05723822
- Testing
- Walkasins
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- RxFunction Inc.
Charcot-Marie-Tooth Disease Type 1A
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A).
- Trial name
- PLEO-CMT (NCT02579759)
- Testing
- PXT3003 dose 1, PXT3003 dose 2
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 323 people
- Sponsor
- Pharnext S.C.A.